Research Analysts Set Expectations for Omnicell Q1 Earnings

Key Points

• Zacks Research lowered Omnicell’s Q1 2028 EPS estimate to $0.40 from $0.41 and maintains a “Strong Sell” rating. Full-year consensus EPS is $1.30.
• Omnicell’s latest quarter exceeded expectations, reporting $0.94 EPS versus the $0.47 consensus and $312.21 million in revenue versus $310.21 million expected. Revenue increased 7.4% year over year.
• Despite mixed analyst views, MarketBeat data shows a “Moderate Buy” consensus rating with a $57.86 target price; institutional investors own 97.7% of the company’s shares.

Omnicell, Inc. (NASDAQ:OMCL - Free Report) - Research analysts at Zacks Research dropped their Q1 2028 earnings per share (EPS) estimates for Omnicell in a report issued on Friday, August 14th. Zacks Research analyst Team now anticipates that the company will post earnings per share of $0.40 for the quarter, down from their previous forecast of $0.41. Zacks Research currently has a "Strong Sell" rating on the stock. The consensus estimate for Omnicell's current full-year earnings is $1.30 per share.

Omnicell (NASDAQ:OMCL - Get Free Report) last posted its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million for the quarter, compared to analyst estimates of $310.21 million. During the same quarter in the prior year, the company earned $0.45 EPS. Omnicell's revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS.

OMCL has been the subject of a number of other research reports. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Omnicell in a research note on Tuesday, August 4th. Piper Sandler reiterated an "overweight" rating and issued a $45.00 target price (down from $55.00) on shares of Omnicell in a report on Monday, August 3rd. Wall Street Zen raised Omnicell from a "buy" rating to a "strong-buy" rating in a research report on Sunday, May 10th. Wells Fargo & Company decreased their price objective on Omnicell from $55.00 to $50.00 and set an "overweight" rating for the company in a research note on Friday, July 31st. Finally, Craig Hallum reissued a "buy" rating and set a $55.00 price objective on shares of Omnicell in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $57.86.

Omnicell Stock Performance

NASDAQ OMCL opened at $36.03 on Tuesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.64 and a quick ratio of 1.43. The company has a market cap of $1.64 billion, a P/E ratio of 42.89, a P/E/G ratio of 1.01 and a beta of 0.98. The stock has a 50-day moving average of $40.60 and a two-hundred day moving average of $39.98. Omnicell has a 1-year low of $29.06 and a 1-year high of $55.00.

Hedge Funds Weigh In On Omnicell

Several hedge funds have recently added to or reduced their stakes in OMCL. Raymond James Financial Inc. acquired a new position in shares of Omnicell in the 2nd quarter valued at $26,000. Versant Capital Management Inc lifted its position in Omnicell by 38.7% in the second quarter. Versant Capital Management Inc now owns 1,053 shares of the company's stock valued at $44,000 after acquiring an additional 294 shares during the last quarter. Clearstead Advisors LLC lifted its position in Omnicell by 12,180.0% in the fourth quarter. Clearstead Advisors LLC now owns 1,228 shares of the company's stock valued at $56,000 after acquiring an additional 1,218 shares during the last quarter. Kemnay Advisory Services Inc. acquired a new position in Omnicell in the fourth quarter valued at $58,000. Finally, Parkside Financial Bank & Trust boosted its stake in Omnicell by 1,708.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 1,338 shares of the company's stock valued at $61,000 after acquiring an additional 1,264 shares in the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source